HMG-CoA Reductase Inhibitors and the Risk of Vertebral Fracture
Open Access
- 1 September 2004
- journal article
- research article
- Published by Oxford University Press (OUP) in Journal of Bone and Mineral Research
- Vol. 19 (9) , 1525-1530
- https://doi.org/10.1359/jbmr.040607
Abstract
Statins inhibit an enzyme in the mevalonate pathway and therefore may affect bone. In this first study on both symptomatic and nonsymptomatic vertebral fractures in the elderly (N = 3469), we show that long‐term statin use is significantly associated with a 50% lower vertebral fracture risk. Randomized trials on statins and fractures, carried out in populations at risk for fractures, are needed. Introduction: Statins are cholesterol‐lowering agents that could potentially affect bone. Previous studies on statin use and fracture risk reported contradictory results and did not include both symptomatic and nonsymptomatic vertebral fractures. Materials and Methods: To examine the association between statin use, vertebral fractures, and lumbar spine BMD, we performed a prospective population‐based cohort study in men and women (N = 3469) ≥55 years of age. These individuals had both baseline and follow‐up spinal X‐rays available. Statin use was obtained from detailed computerized pharmacy data, and the total number of days of exposure before second X‐ray was calculated. A multivariate logistic regression model was fitted to calculate odds ratios and CIs. Results: During a mean follow‐up of 6.5 years, 176 incident vertebral fractures occurred. There were 508 statin users and 16 exposed cases. The adjusted relative risk for incident vertebral fracture in users of statins (compared with nonusers) was 0.58 (95% CI, 0.34‐0.99). The relative risk decreased on higher cumulative use to 0.52 (95% CI, 0.28‐0.97) for use for more than 365 days during the study period. Use of (the hydrophilic statin) pravastatin and use of nonstatin cholesterol‐lowering drugs was not significantly associated with vertebral fracture risk. Statin use was not significantly associated with lumbar spine BMD. Conclusion: Statin use is associated with a lower risk of vertebral fracture. Randomized clinical trials in a population at risk for fracture are needed to examine this association.Keywords
This publication has 32 references indexed in Scilit:
- Attrition in longitudinal studiesJournal of Clinical Epidemiology, 2002
- Pitavastatin Enhanced BMP-2 and Osteocalcin Expression by Inhibition of Rho-Associated Kinase in Human OsteoblastsBiochemical and Biophysical Research Communications, 2001
- Compactin and Simvastatin, but Not Pravastatin, Induce Bone Morphogenetic Protein-2 in Human Osteosarcoma CellsBiochemical and Biophysical Research Communications, 2000
- Compactin Suppresses Bone Resorption by Inhibiting the Fusion of Prefusion Osteoclasts and Disrupting the Actin Ring in OsteoclastsJournal of Bone and Mineral Research, 2000
- The association between age and bone mineral density in men and women aged 55 years and over: The Rotterdam StudyBone and Mineral, 1994
- The assessment of vertebral deformity: A method for use in population studies and clinical trialsOsteoporosis International, 1993
- Incidence of clinically diagnosed vertebral fractures: A population-based study in rochester, minnesota, 1985-1989Journal of Bone and Mineral Research, 1992
- Cardiovascular disease risk profilesAmerican Heart Journal, 1991
- Assessment of patient satisfaction in activities of daily living using a modified stanford health assessment questionnaireArthritis & Rheumatism, 1983
- “Mini-mental state”Journal of Psychiatric Research, 1975